GSK1349572

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infection, Human Immunodeficiency Virus

Conditions

Infection, Human Immunodeficiency Virus, HIV Infections

Trial Timeline

Feb 15, 2010 → Apr 5, 2010

About GSK1349572

GSK1349572 is a phase 1 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01068925. Target conditions include Infection, Human Immunodeficiency Virus, HIV Infections.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT01332565Phase 1Completed
NCT01231529Phase 1Completed
NCT01068925Phase 1Completed
NCT00774111Phase 1Completed

Competing Products

20 competing products in Infection, Human Immunodeficiency Virus

See all competitors
ProductCompanyStageHype Score
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1944ModernaPhase 1
0
mRNA-1189ModernaPhase 2
0
mRNA-1647ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0
mRNA-1195.1ModernaPhase 1
0
mRNA-1647ModernaPhase 1
0
mRNA-1647ModernaPhase 3
0
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
BSG005Alkem LaboratoriesPhase 1/2
39
Zotatifin + PlaceboeFFECTOR TherapeuticsPhase 1
19
AAVLP-HPV + Placebo2A PharmaPhase 1
19
CT-P59CelltrionPhase 1
29
CT-P63 + PlaceboCelltrionPhase 1
29